We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Puretech Health Plc | PRTC | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 8.50 | 4.00% | 221.00 | 12:27:25 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 219.00 | 211.00 | 225.00 | 212.50 |
| Industry Sector |
|---|
| PHARMACEUTICALS & BIOTECHNOLOGY |
| Top Posts |
|---|
Posted at 22/4/2024 11:45 by linton5 Oxb starting to motor now I see prtc pulled up at the 1st 🐎 |
Posted at 15/4/2024 16:31 by crazycoops There are several companies that are UK listed (e.g. SPSY, SOM) that are US based and the US tax rules for withholding tax apply. I presume the same is true for PRTC being headquartered in Boston. |
Posted at 15/4/2024 12:16 by crazycoops I just picked this up from Mark Simpson on Stockopedia. To avoid withholding tax on a tender offer from a US based company, investors will need to complete a Section 302 "Certification of Treatment of Tender Payment" form. This is separate from a W-8BEN form that most investors will already be familiar with. Worth noting for anyone considering taking up the PRTC tender offer. |
Posted at 25/3/2024 16:47 by edwardt buy prtc - cheaper way of getting involved in seaport? |
Posted at 17/3/2024 07:43 by 2theduke Rimou / do you think the c$294m due to prtc on completion of krtx buy out is gross of tax ? If so that tax rate needs to be taken in to account for nav.Otherwise I agree with your views and values. |
Posted at 16/3/2024 16:37 by colinblackbourn 27 September 2023PureTech Health plcPureTech Announces the Appointment of Robert Lyne as Chief Portfolio OfficerPureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases , today announced the appointment of Robert Lyne as Chief Portfolio Officer. Robert brings a decade of experience in international life science deals and portfolio management, along with governance and executive team leadership experience. Robert is expected to join PureTech by early January 2024."We are excited to welcome Rob to our management team and pleased to add a dedicated presence representing our senior leadership team in the UK as we work to deliver impactful new treatments for patients," said Daphne Zohar, Founder and Chief Executive Officer of PureTech. "His extensive legal, operational and UK listed IP commercialization experience is complementary to PureTech's own hub-and-spoke business model. We are looking forward to working together closely as we realize the full potential of both our Wholly Owned Programs and Founded Entity stakes and royalties."Mr. Lyne joins PureTech from Arix Bioscience plc, a transatlantic venture capital company focused on investing in innovative biotechnology companies, where he served as General Counsel and Chief Operating Officer before being appointed Chief Executive Officer in April 2021. He began his career as a lawyer at international law firm Bird & Bird LLP in London before moving to Touchstone Innovations, a London listed biotech and technology investor, which was acquired in 2017. He has worked on over 80 venture capital financings in Europe and North America as well as multiple trade exits and IPOs. As an experienced UK plc executive, Mr. Lyne has broad experience formulating and implementing corporate strategy. Mr. Lyne has a BA from the University of Oxford and an LLB from Oxford Brookes University."I am delighted to be joining the management team at PureTech during such an exciting time in the Company's growth," said Mr. Lyne. "As pioneers of the hub-and-spoke model in the biotechnology sector, PureTech's approach is aligned with my own experience and ambitions. They are highly innovative in their approach to both science and business, which has led to the team delivering an impressive track record of developing new therapies with transformational potential. I look forward to working with the skilled team at PureTech and its outstanding network of advisors to further drive the Company forward." |
Posted at 14/3/2024 13:48 by lendmeafiver If it’s now legally binding, or will be on Monday, then PRTC should announce what they plan to do in terms of distribution rather than letting the market speculate. |
Posted at 13/3/2024 15:37 by lendmeafiver Roughly when do we expect PRTC to announce what they are going to do with the Karuna proceeds? |
Posted at 27/2/2024 07:15 by takeiteasy 27 February 2024PureTech Health plc PureTech Founded Entity Akili Announces Positive Results from Shionogi's Phase 3 Clinical Trial of Localized Version of Akili's EndeavorRx ® for Pediatric ADHD Patients in Japan Japanese Product Now Under Review for Nationwide Marketing Approval PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that its Founded Entity Akili, Inc. (Nasdaq: AKLI) announced that its Japanese partner Shionogi & Co. Ltd has submitted Akili's digital therapeutic SDT-001 for marketing approval with the Ministry of Health, Labor, and Welfare. SDT-001 is the Japanese, localized version of Akili's AKL-T01 (marketed as EndeavorRx® in the United States), which has previously been authorized by the U.S. Food and Drug Administration (FDA) as the world's first prescription digital therapeutic for improving attentional functioning in pediatric ADHD patients aged 8 to 17. "We are pleased by this additional validation of Akili's EndeavorRx," said Eric Elenko, Ph.D., Chief Innovation Officer at PureTech. "This game-changing technology is now poised to address the needs of pediatric patients with ADHD in Japan if approved, and this exciting milestone is yet another example of PureTech's contribution to changing the lives of patients in need." Feb 2024 presentation says we own 14.6% of Akilii so not a bad shout for Akili up 125% (yes, one hundred and twenty five - no misprint!) on this news...dyor etc |
Posted at 12/1/2024 08:20 by return_of_the_apeman daijavu,Some might have been bought back by PRTC, however as seen by the figures below, the UT trade size has been above the size of the buy back Date UT size Buyback size 09/01 317,412 92,828 10/01 200,555 117,693 11/01 41,859 116,937 As Colinblackbourn points out the buy backs by PRTC can be up to 25% of daily volume, my point is that someone has offloaded over £1million at the end of day auction over the past 3 days - I have no idea who or why For every seller there is a buyer but why sell now Perhaps I will put a limit order in at the end of the day to see if I can pick up a few cheap ones gla |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
